Member Type: Research & Educational Institutions
At the OHSU Knight Cancer Institute, we see a world without cancer. As pioneers in personalized cancer medicine, we continue to change the way the world understands and fights this disease. The most celebrated cancer discovery in a generation—the targeted drug Gleevec—was developed at OHSU by Brian J. Druker, M.D., the director of the OHSU Knight Cancer Institute. The Knight is bringing together leading cancer basic and clinical researchers to transform cancer. To enable our research efforts and stimulate partnering opportunities, we have established CLIA/CAP-certified Diagnostics Laboratory and BioLibrary resources. As we build an integrated and comprehensive approach to personalize cancer therapies and transform the face of cancer treatment, we are always looking for partners who share our vision and would like to help us end cancer as we know it.